nd vancomycin for intervening infections during the study. The d...Ellie J. Goldstein M.D. from the R.M. Alden Research Laboratory in S...In an oral presentation Dale N. Gerding M.D. an investigator from t...

nd vancomycin for intervening infections during the study. The data indicated fidaxomicin was a superior therapy to vancomycin in preventing recurrence and in promoting global cure in patients requiring concomitant antibiotics. The analysis from the Phase 3 trials indicated that in patients receiving concomitant antibiotics, those treated with fidaxomicin versus vancomycin had a significantly lower CDI recurrence rate (17% vs. 28%, p=0.039) and had a significantly improved global cure rate (73% vs. 60%, p=0.013). At the same time, among subjects who received no concomitant antibiotics, recurrence in vancomycin-treated subjects was double that of fidaxomicin-treated subjects (23% vs. 11.5%, p<0.001).

Ellie J. Goldstein, M.D., from the R.M. Alden Research Laboratory in Santa Monica, CA, presented data on the antimicrobial susceptibilities of C. difficile isolates to fidaxomicin, vancomycin, metronidazole, and rifaximin cultured from fecal specimens collected from patients at study entry and at failure/recurrence in Optimer's second Phase 3 clinical trial. The data showed that there was no relationship between MICs of baseline CDI isolates and clinical outcome for fidaxomicin but there was a one dilution difference for vancomycin between cure and failure. The MIC90s were generally low for fidaxomicin, vancomycin, and metronidazole but the BI isolates generally had higher MICs for the four drugs tested than the BK, CF, DH, G, J, and Y group isolates. No resistance to either fidaxomicin or vancomycin developed during the 10-day treatment in this or in the first Phase 3 trial. Rifaximin resistant strains, 8.1% of all strains, were isolated in both treatment groups with MIC90s higher in treatment failures than cures.

In an oral presentation, Dale N. Gerding, M.D., an investigator from the Hines VA Hospital in Chicago, IL, presented data on the C. difficile strain types isolated in Optimer's two fidaxomicin '/>"/>

(Date:3/3/2015)... 3, 2015 Adaptive Biotechnologies announced today that ... its Board of Director as Chair of the Audit ... Group, Chad oversees all finance, treasury and accounting functions. ... core finance, treasury and accounting functions, and led the ... In 2013, he was named Puget Sound Business Journal,s ...

(Date:3/3/2015)... , March 3, 2015 Regenicin, Inc. (OTC ... specializing in the development of and commercialization of regenerative ... and organs, announced today that it has received the ... Amarantus Bioscience Holdings, Inc. (OTC Bulletin Board: ... Agreement, Amarantus made the final payments due to Regenicin ...

... Internet is an integral place of business, the online reality ... credible Web sites. , ,Many Internet surfers often believe ... Their intuition is based on a number of surface-level factors. ... when it appears in the natural results of a search ...

... executive summaries of their businesses for angel investors' perusal ... , ,The Wisconsin Angel Network will launch ... with entrepreneurs based on the investors' market interests. , ... pipeline, has been designed to be a single source ...

... of other states across the Midwest, and you'll find ... but instead a reflection on the fact that most ... ,Minnesota has the Twin Cities of Minneapolis-St. Paul ... Clinic in Rochester. Illinois has Chicago, with Northwestern University ...

(Date:2/12/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE SERVICES ... NXT-ID,s position in the emerging "Internet of Things" by ... multiple devices to collaborate with one another to improve ...

(Date:2/5/2015)... 5, 2015 Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...

... PhD student are part of a research team that ... oxygen levels in the oceans high enough to establish ... By examining ancient-ocean sediments, Kurt Konhauser, student ... last glacier to encircle Earth receded, leaving behind glacial ...

... 2010Mary Ann Liebert, Inc. announces the release of a ... neuroscience, Brain Connectivity . This timely new journal ... basic and clinical neuroscience research aimed at better understanding ... how these connections are altered by neurological disorders. ...

... 28, 2010 For Immediate Release A group ... Scripps Translational Science Institute has published a paper that ... variations that reveal whether people are predisposed to developing ... our modern genetic age, the entire DNA sequences, or ...

... incorporating a wide range of next-generation features ... a new standard for flexible laboratory solutions. ... including pipetting, dilution, dispensing, and integrations ... as powerful and flexible as it is ...